When pharmacologist Ravindra Ghooi learned in 1996 that his mother had terminal breast cancer, he began to investigate whether he could obtain morphine, in case she needed pain relief at the end of her life. But a morphine prescription in India at that time, even for the dying, was a rare thing: most states required four or five different licences to buy painkillers such as morphine, and there were harsh penalties for minor administrative errors. Few pharmacies stocked opioids and it was a rare doctor who held the necessary paperwork to prescribe them. Ghooi, who is now a consultant at Cipla Palliative Care and Training Centre in Pune, used his connections to ask government and industry officials if there was a straightforward way of obtaining morphine for his mother. “Everybody agreed to give me morphine,” he recalls, “but they said they’d give it to me illegally.”
He didn’t know it at the time, but when chemist Matthew Todd posted a request for help on The Synaptic Leap, a website devoted to open-source biomedical research, he was sowing the seeds for a rivalry between an open initiative and a contract-research organization hired by the World Health Organization to reach the same goal.
The aim of both projects, run in 2010, was to produce a safer, low-cost version of praziquantel, a treatment for the tropical parasitic infection schistosomiasis. Up until that point, the treatment contained two enantiomers (mirror-image versions of the molecule that have slightly different properties) of praziquantel. One enantiomer has no effect on the parasite, but gives the drug a bitter taste. Eliminating this undesirable form could reduce side effects and help more patients to complete their treatment. The pure drug needed to be affordable. Todd, who is at the University of Sydney in Australia, thought that an open project was the best way to achieve this. “Open is very well-suited for neglected diseases,” he says. “The pay-off of secrecy is not very large.” Continue reading
I reported and wrote an infographic on the epidemiology of liver cancer. It was a good growing experience to work with a designer and an editor on a piece of visual, data-oriented journalism. I learned a lot and ended up wanting to experiment more with conveying data visually, with words and stories as a complement, rather than the other way around. I’m looking forward to the next opportunity.
To best see the visual elements of the infographic, I recommend checking out the PDF below rather than the HTML web version.
For something that took years to arrive, Madrid’s public bicycles sure get off to a fast start. Pedal once and the 36-volt, 10-ampere, electric motors will give you a sudden boost. Going up one of Madrid’s many hills, it is a welcome aid. Downhill, the burst jars. But riders can disable the boost by not pedaling, and moderate it with electric controls on the handlebars. With a little practice, the bikes begin to feel like underpowered motor scooters. “Our major goal is to move journeys that are now done by car to the bicycles,” says Elisa Barahona, Madrid’s director of sustainability and environment.